Stephanie Gold
Cornell University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stephanie Gold.
Inflammatory Bowel Diseases | 2017
Stephanie Gold; Shirley A. Cohen-Mekelburg; Yecheskel Schneider; Nicole T. Shen; Alec Faggen; Amanda Rupert; Ellen J. Scherl; Brian P. Bosworth
Background: Infliximab (IFX) is commonly used in patients with inflammatory bowel disease. One common side effect of IFX is an acute infusion reaction. Despite the lack of evidence supporting their use, clinicians use various premedications to prevent acute reactions. We evaluated the effectiveness of premedications in the prevention of acute IFX infusion reactions. Methods: A retrospective cohort study was performed identifying patients with a diagnosis of inflammatory bowel disease who received IFX at our institution. Information about each IFX infusion was recorded, including the dose, infusion rate, use of premedications, and any reactions. Infusions were stratified into low and high risk. In the high- and low-risk groups, the relative risk was calculated for each premedication combination used in our institution. Results: Seven hundred seventy-three patients were identified; 578 patients (7090 infusions) met inclusion criteria and were included for analysis. Nine hundred eighty-six high-risk infusions were isolated; 620 (62.8%) of these infusions were administered with premedications (diphenhydramine and/or hydrocortisone) and 53 (5.4%) reactions occurred. Six thousand one hundred four low-risk infusions were identified; 2253 (36.9%) of these infusions had premedications and 61 (1.0%) reactions occurred. In both groups, none of the premedications used resulted in a significantly lower reaction rate compared with no premedication use. Conclusions: In both the high- and low-risk cohorts in this study, premedication use was not effective in reducing the rate of acute IFX reactions. Given this, routine premedication use is not recommended without future randomized control trials to demonstrate efficacy.
ACG Case Reports Journal | 2018
Stephanie Gold; Shirley A. Cohen-Mekelburg; Russell Rosenblatt; Jose Jessurun; Reem Z. Sharaiha; Karim J. Halazun; David Wan
Small bowel bleeding should be considered in patients who continue to bleed despite a negative upper endoscopy and colonoscopy. The differential diagnosis of small bowel bleeding can include infection, inflammatory conditions, vascular malformations, and, rarely, malignancy. This report demonstrates a rare, primary, small bowel, reticular cell sarcoma presenting as an overt gastrointestinal bleed. These tumors are difficult to diagnose because they are rarely seen on traditional cross-sectional imaging and can present with multiple synchronous lesions throughout the intestinal tract.
Digestive Diseases and Sciences | 2018
Shirley A. Cohen-Mekelburg; Stephanie Gold; Yecheskel Schneider; Madison Dennis; Clara Oromendia; Heather Yeo; Fabrizio Michelassi; Ellen J. Scherl
Gastroenterology | 2017
Yecheskel Schneider; Monica Saumoy; Shirley A. Cohen-Mekelburg; Stephanie Gold; Ellen J. Scherl
Journal of Crohns & Colitis | 2018
Shirley A. Cohen-Mekelburg; Russell Rosenblatt; Stephanie Gold; Robert Burakoff; Akbar K. Waljee; Sameer D. Saini; Bruce R. Schackman; Ellen J. Scherl; Carl V. Crawford
Gastroenterology | 2018
Shirley A. Cohen-Mekelburg; Russell Rosenblatt; Stephanie Gold; Ellen J. Scherl; Robert Burakoff; Mark Unruh
Gastroenterology | 2018
Shirley A. Cohen-Mekelburg; Stephanie Gold; Russell Rosenblatt; Ellen J. Scherl; Robert Burakoff; Carl V. Crawford
Gastroenterology | 2018
Stephanie Gold; Cynthia M. Magro; Ellen J. Scherl
Gastroenterology | 2018
Stephanie Gold; Shirley A. Cohen-Mekelburg; Yecheskel Schneider; Ellen J. Scherl
Gastroenterology | 2018
Stephanie Gold; Shirley A. Cohen-Mekelburg; Paul J. Christos; Yecheskel Schneider; Brian P. Bosworth; Ellen J. Scherl